Dec 8, 2025 04:46AM Atossa Genetics (ATOS) PT Raised to $8 at Ascendiant Capital

Dec 5, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Dec 4, 2025 08:01AM Atossa Therapeutics meets with FDA on cancer drug development strategy

Dec 2, 2025 08:01AM Insilico Medicine and Atossa publish study on brain cancer treatment

Nov 17, 2025 09:09AM Atossa highlights potential for endoxifen in muscular dystrophy treatment

Nov 12, 2025 04:23PM Atossa Genetics (ATOS) Misses Q3 EPS by 1c

Oct 14, 2025 07:53AM Atossa Therapeutics names Mark Daniel as chief financial officer

Oct 7, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Oct 6, 2025 08:04AM Atossa streamlines breast cancer trial to cut costs and focus on 2026 NDA plans

Oct 1, 2025 08:32AM Atossa Therapeutics appoints Janet Rea as senior VP of R&D

Sep 9, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Sep 8, 2025 08:30AM Atossa requests FDA meeting for endoxifen breast cancer drug development

Aug 29, 2025 09:00AM NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 12, 2025 09:46AM Atossa Genetics (ATOS) Misses Q2 EPS by 1c

Aug 1, 2025 09:00AM Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 6, 2025 05:21AM Atossa Genetics (ATOS) PT Raised to $7.50 at Ascendiant Capital

Jun 5, 2025 08:39AM Craig-Hallum Starts Atossa Genetics (ATOS) at Buy, 'Refining The Gold Standard Therapy For Breast Cancer'

May 20, 2025 09:00AM Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 13, 2025 05:31PM Atossa Genetics (ATOS) Tops Q1 EPS by 2c

May 2, 2025 09:00AM Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Apr 30, 2025 08:45AM Atossa Therapeutics (ATOS) Issued U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025 08:47AM Atossa Therapeutics (ATOS) Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR

Apr 22, 2025 08:45AM Atossa Therapeutics (ATOS) Issues New U.S. Patent

Mar 26, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Mar 11, 2025 08:15AM Atossa Therapeutics (ATOS) Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Jan 30, 2025 08:17AM Atossa Therapeutics (ATOS) Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Jan 23, 2025 08:15AM Atossa Therapeutics (ATOS) Issues Letter to Shareholders

Dec 11, 2024 08:15AM Atossa Therapeutics (ATOS) Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Nov 13, 2024 06:54AM Atossa Genetics (ATOS) PT Raised to $7 at H.C. Wainwright

Nov 5, 2024 08:05AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Nov 4, 2024 06:30AM Atossa Therapeutics (ATOS) Reports Positive KARISMA-Endoxifen Trial Results

Oct 31, 2024 08:15AM Atossa Therapeutics (ATOS) Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Sep 10, 2024 08:30AM Atossa Therapeutics (ATOS) Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Aug 28, 2024 08:31AM Atossa Therapeutics (ATOS) Granted Additional Patent Protection for Endoxifen

Aug 21, 2024 11:37AM Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 21, 2024 08:37AM Atossa Therapeutics (ATOS), Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 12, 2024 05:06PM Atossa Genetics (ATOS) Tops Q2 EPS by 1c

Jul 2, 2024 04:15PM Atossa Therapeutics (ATOS) Appoints Heather Rees as CFO

Jul 1, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)

Jun 28, 2024 08:32AM Atossa Therapeutics (ATOS) Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer